Type 2 Med Is Approved
The type 2 diabetes medication linagliptin (Tradjenta) received Food and Drug Administration approval today. Linagliptin is in a class of prescription medications known as DPP-4 inhibitors, which lower blood glucose by increasing the body's production of insulin after meals. The medication, taken as a once-daily tablet, can be used alone or in combination with other type 2 meds.
Unlike the other DPP-4 inhibitors saxagliptin (Onglyza) and sitagliptin (Januvia) currently on the market, linagliptin isn't primarily excreted through the kidneys, according to Boehringer Ingelheim Pharmaceuticals, which developed the medication with Eli Lilly Co. As a result, linagliptin may not require dose adjustment for people with kidney problems. DPP-4 inhibitors are not associated with weight gain or hypoglycemia (low blood glucose).